Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld) phenotype

Journal of Experimental Medicine

Volumn 191, Issue 1, 2000, Pages 89-96

  Körner, Heinrich ^a   Cretney, Erika ^c   Wilhelm, Patricia ^a   Kelly, Janice M ^c   Röllinghoff, Martin ^a   Sedgwick, Jonathon D ^b   Smyth, Mark J ^c  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b MERCK RESEARCH LABORATORIES   (United States)

^c AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

Apoptosis; Fas ligand; Gene targeting; Lymphadenopathy; Lymphoproliferation

Indexed keywords

FAS ANTIGEN; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DEATH; HYPERGAMMAGLOBULINEMIA; LYMPHADENOPATHY; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPLENOMEGALY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; FAS LIGAND PROTEIN; GERMINAL CENTER; LYMPHOPROLIFERATIVE DISORDERS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C3H; MICE, KNOCKOUT; PHENOTYPE; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0343938868     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.191.1.89     Document Type: Article

References (36)

1. Smith, C.A., T. Farrah, and R.G. Goodwin. 1994. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 76:959-962.
2. Lynch, D.H. 1996. The role of FasL and TNF in the homeostatic regulation of immune responses. Adv. Exp. Med. Biol. 406:135-138.
3. Krammer, P.H. 1999. CD95 (APO-1/Fas)-mediated apoptosis: live and let die. Adv. Immunol 71:163-210.
4. Bazzoni, F., and B. Beutler. 1996. Seminars in Medicine of the Beth Israel Hospital, Boston: The Tumour Necrosis Factor Ligand and Receptor Families. N. Engl. J. Med. 334:1717-1725.
5. Cohen, P.L., and R.A. Eisenberg. 1991. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 9:243-269.
6. Nagata, S. 1994. Fas and Fas ligand: a death factor and its receptor. Adv. Immunol. 57:129-144.
7. Lynch, D.H., M.L. Watson, M.R. Alderson, P.R. Baum, R.E. Miller, T. Tough, M. Gibson, T. Davis-Smith, C.A. Smith, K. Hunter, et al. 1994. The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity. 1:131-136.
8. Takahashi, T., M. Tanaka, C.I. Brannan, N.A. Jenkins, N.G. Copeland, T. Suda, and S. Nagata. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 76:969-976.
9. Theofilopoulos, A.N., and F.J. Dixon. 1981. Etiopathogenesis of murine SLE. Immunol. Rev. 55:179-216.
10. Roths, J.B., E.D. Murphy, and E.M. Eicher. 1984. A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J. Exp. Med. 159:1-20.
11. Izui, S., V.E. Kelley, K. Masuda, H. Yoshida, J.B. Roths, and E.D. Murphy. 1984. Induction of various autoantibodies by mutant gene lpr in several strains of mice. J. Immunol. 133:227-233.
12. Beutler, B., and C. van Huffel. 1994. Unraveling function in the TNF ligand and receptor families. Science. 264:667-668.
13. Pfeffer, K., T. Matsuyama, T.M. Kündig, A. Wakeham, K. Kishihara, A. Shahinian, K. Wiegmann, P.S. Ohashi, M. Krönke, and T.W. Mak. 1993. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 73:457-467.
14. Rothe, J., W. Lesslauer, H. Lötscher, Y. Lang, P. Köbel, F. Köntgen, A. Althage, R. Zinkernagel, M. Steinmetz, and H. Blüethmann. 1993. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 364:798-802.
15. Erickson, S.L., F.J. de Sauvage, K. Kikly, K. Carver-Moor, S. Pitts-Meek, N. Gillett, K.C. Sheehan, R.D. Schreiber, D.V. Goeddel, and M.W. Moore. 1994. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature. 372:560-563.
16. Pasparakis, M., L. Alexopoulou, V. Episkopou, and G. Kollias. 1996. Immune and inflammatory responses in TNF-α-deficient mice: a critical requirement for TNF-α in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med. 184:1397-1411.
17. Körner, H., M. Cook, D.S. Riminton, F.A. Lemckert, R. Hoek, B. Ledermann, F. Köntgen, B. Fazekas de St. Groth, and J.D. Sedgwick. 1997. Distinct roles for lymphotoxin-α and tumor necrosis factor in organogenesis and spatial organization of lymphoid tissue. Eur. J. Immunol. 27:2600-2609.
18. Ngo, V.N., H. Körner, M.D. Gunn, K.N. Schmidt, S.D. Riminton, M.D. Cooper, J.L. Browning, J.D. Sedgwick, and J.G. Cyster. 1999. Lymphotoxin α/β and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J. Exp. Med. 189:403-412.
19. Zhou, T., C.K. Edwards, P. Yang, Z. Wang, H. Bluethmann, and J.D. Mountz. 1996. Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor 1. J. Immunol. 156:2661-2665.
20. Hoek, R.C., M.C. Kortekaas, and J.D. Sedgwick. 1997. Allele-specific PCR analysis for detection of the gld Fas-ligand point mutation. J. Immunol. Methods. 210:109-112.
21. Giese, T., and W.F. Davidson. 1995. In CD8+ T cell-deficient lpr/lpr mice, CD4+B220+ and CD4+B220-T cells replace B220+ double-negative T cells as the predominant populations in enlarged lymph nodes. J. Immunol. 154:4986-4995.
22. Matsumoto, M., S. Manathasan, M.H. Nahm, F. Baranyay, J.J. Peschon, and D.D. Chaplin. 1996. Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers. Science. 271:1289-1291.
23. Le Hir, M., H. Bluethmann, M.H. Kosco-Vilbois, M. Müller, F. di Padova, M. Moore, B. Ryffel, and H.P. Engster. 1996. Differentiation of follicular dendritic cells and full antibody responses require tumor necrosis factor receptor-1 signaling. J. Exp.Med. 183:2367-2372.
24. Tartaglia, L.A., R.F. Weber, I.S. Figari, C. Reynolds, M.A. Palladino, Jr., and D.V. Goeddel. 1991. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc. Natl. Acad. Sci. USA. 88:9292-9296.
25. McDermott, M., F.I. Aksentijevich, J. Galon, E.M. McDermott, B.W. Ogunkolade, M. Centola, E. Mansfield, M. Gadina, L. Karenko, T. Pettersson, et al. 1999. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 97:133-144.
26. Vella, A.T., J.E. McCormack, P.S. Linsley, J.W. Kappler, and P. Marrack. 1995. Lipopolysaccharide interferes with the induction of peripheral T cell death. Immunity. 2:261-270.
27. Salmon, M., D. Scheel-Toellner, A.P. Huissoon, D. Pilling, N. Shamsadeen, H. Hyde, A.D. D'Angeac, P.A. Bacon, P. Emery, and A.N. Akbar. 1997. Inhibition of T cell apoptosis in the rheumatoid synovium. J. Clin. Invest. 99:439-446.
28. Davidson, W.F., K.L. Holmes, J.B. Roths, and H.C. Morse III. 1985. Immunologic abnormalities of mice bearing the gld mutation suggest a common pathway for murine nonmalignant lymphoproliferative disorders with autoimmunity. Proc. Natl. Acad. Sci. USA. 82:1219-1223.
29. Davidson, W.F., T. Giese, and T.N. Fredrickson. 1998. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J. Exp. Med. 187:1825-1838.
30. Sedgwick, J.D., D.S. Riminton, J.G. Cyster, and H. Körner. 1999. Tumor necrosis factor: a master regulator of leukocyte movement. Immunol. Today. In press.
31. Zheng, L., G. Fisher, R.E. Miller, J. Peschon, D.H. Lynch, and M.J. Lenardo. 1995. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature. 377:348-351.
32. Steinberg, A.D., J.B. Roths, E.D. Murphy, R.T. Steinberg, and E.S. Raveche. 1980. Effects of thymectomy or androgen administration upon the autoimmune disease of MRL/Mp-lpr/lpr mice. J. Immunol. 125:871-873.
33. Mountz, J.D., H.R. Smith, R.L. Wilder, J.P. Reeves, and A.D. Steinberg. 1987. CS-A therapy in MRL-lpr/lpr mice: amelioration of immunopathology despite autoantibody production. J. Immunol. 138:157-163.
34. + T cells to lymphoproliferation and autoantibody production in MRL-lpr/lpr mice. J. Exp. Med. 167:1713-1718.
35. Asensi, V., K. Kimeno, I. Kawamura, M. Sakumoto, and K. Nomoto. 1989. Treatment of autoimmune MRL/lpr mice with anti-B220 monoclonal antibody reduces the level of anti-DNA antibodies and lymphadenopathies. Immunology. 68:204-208.
36. de Alboran, I.M., J.A. Gonzalo, G. Kroemer, E. Leonardo, M.A. Marcos, and C. Martinez. 1992. Attenuation of autoimmune disease and lymphocyte accumulation in MRL/lpr mice by treatment with anti-Vβ8 antibodies. Eur. J. Immunol. 22:2153-2158.